VEGFA and colorectal cancer: Bevacizumab (anti-VEGF monoclonal antibodies) and sorafenib and sunitinib (selective VEGFRs tyrosine kinase inhibitors) have been approved by the FDA for clinical use in breast cancer, lung cancer, colorectal cancer, metastasis, and hepatocellular carcinoma.